Cargando…
Genome Editing among Bioethics and Regulatory Practices
In the last decade, genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the deba...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774098/ https://www.ncbi.nlm.nih.gov/pubmed/35053161 http://dx.doi.org/10.3390/biom12010013 |
_version_ | 1784636254789304320 |
---|---|
author | Mandrioli, Mauro |
author_facet | Mandrioli, Mauro |
author_sort | Mandrioli, Mauro |
collection | PubMed |
description | In the last decade, genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the debate about the bioethics and the regulatory practices of genome editing is still far from satisfactory answers. This delay results from an excessive emphasis on the effectiveness of the genome editing technologies that is relevant for the regulatory practices, but not at a bioethical level. Indeed, other factors (such as accessibility and acceptability) could make these techniques not accepted at the bioethical level, even in the presence of their 100% effectiveness. |
format | Online Article Text |
id | pubmed-8774098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87740982022-01-21 Genome Editing among Bioethics and Regulatory Practices Mandrioli, Mauro Biomolecules Review In the last decade, genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the debate about the bioethics and the regulatory practices of genome editing is still far from satisfactory answers. This delay results from an excessive emphasis on the effectiveness of the genome editing technologies that is relevant for the regulatory practices, but not at a bioethical level. Indeed, other factors (such as accessibility and acceptability) could make these techniques not accepted at the bioethical level, even in the presence of their 100% effectiveness. MDPI 2021-12-22 /pmc/articles/PMC8774098/ /pubmed/35053161 http://dx.doi.org/10.3390/biom12010013 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mandrioli, Mauro Genome Editing among Bioethics and Regulatory Practices |
title | Genome Editing among Bioethics and Regulatory Practices |
title_full | Genome Editing among Bioethics and Regulatory Practices |
title_fullStr | Genome Editing among Bioethics and Regulatory Practices |
title_full_unstemmed | Genome Editing among Bioethics and Regulatory Practices |
title_short | Genome Editing among Bioethics and Regulatory Practices |
title_sort | genome editing among bioethics and regulatory practices |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774098/ https://www.ncbi.nlm.nih.gov/pubmed/35053161 http://dx.doi.org/10.3390/biom12010013 |
work_keys_str_mv | AT mandriolimauro genomeeditingamongbioethicsandregulatorypractices |